These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9855069)

  • 1. Outcome of ulcerative colitis after treatment with transdermal nicotine.
    Guslandi M; Tittobello A
    Eur J Gastroenterol Hepatol; 1998 Jun; 10(6):513-5. PubMed ID: 9855069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of a single course of nicotine treatment in acute ulcerative colitis: remission maintenance in a 12-month follow-up study.
    Guslandi M
    Int J Colorectal Dis; 1999 Nov; 14(4-5):261-2. PubMed ID: 10647637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal nicotine for induction of remission in ulcerative colitis.
    McGrath J; McDonald JW; Macdonald JK
    Cochrane Database Syst Rev; 2004 Oct; (4):CD004722. PubMed ID: 15495126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot trial of nicotine patches as an alternative to corticosteroids in ulcerative colitis.
    Guslandi M; Tittobello A
    J Gastroenterol; 1996 Aug; 31(4):627-9. PubMed ID: 8844492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine.
    Guslandi M; Frego R; Viale E; Testoni PA
    Can J Gastroenterol; 2002 May; 16(5):293-6. PubMed ID: 12045777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal nicotine as maintenance therapy for ulcerative colitis.
    Thomas GA; Rhodes J; Mani V; Williams GT; Newcombe RG; Russell MA; Feyerabend C
    N Engl J Med; 1995 Apr; 332(15):988-92. PubMed ID: 7885427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal nicotine for active ulcerative colitis.
    Pullan RD; Rhodes J; Ganesh S; Mani V; Morris JS; Williams GT; Newcombe RG; Russell MA; Feyerabend C; Thomas GA
    N Engl J Med; 1994 Mar; 330(12):811-5. PubMed ID: 8114833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis.
    Thomas GA; Rhodes J; Ragunath K; Mani V; Williams GT; Newcombe RG; Russell MA; Feyerabend C
    Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):769-76. PubMed ID: 8864674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial.
    Sandborn WJ; Tremaine WJ; Offord KP; Lawson GM; Petersen BT; Batts KP; Croghan IT; Dale LC; Schroeder DR; Hurt RD
    Ann Intern Med; 1997 Mar; 126(5):364-71. PubMed ID: 9054280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study.
    Sandborn WJ; Tremaine WJ; Leighton JA; Lawson GM; Zins BJ; Compton RF; Mays DC; Lipsky JJ; Batts KP; Offord KP; Hurt RD; Green J
    Aliment Pharmacol Ther; 1997 Aug; 11(4):663-71. PubMed ID: 9305473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal nicotine for ulcerative colitis.
    Guslandi M; Tittobello A
    Ann Intern Med; 1997 Sep; 127(6):492; author reply 492-3. PubMed ID: 9313013
    [No Abstract]   [Full Text] [Related]  

  • 14. A practical guide to the management of distal ulcerative colitis.
    Ardizzone S; Bianchi Porro G
    Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
    Pica R; Cassieri C; Cocco A; Zippi M; Marcheggiano A; De Nitto D; Avallone EV; Crispino P; Occhigrossi G; Paoluzi P
    Dig Liver Dis; 2015 Nov; 47(11):933-7. PubMed ID: 26391602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results.
    Sandborn WJ
    Am J Gastroenterol; 1999 May; 94(5):1161-71. PubMed ID: 10235187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
    Bokemeyer B; Hommes D; Gill I; Broberg P; Dignass A
    J Crohns Colitis; 2012 May; 6(4):476-82. PubMed ID: 22398060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis.
    Green JT; Thomas GA; Rhodes J; Evans BK; Russell MA; Feyerabend C; Fuller GS; Newcombe RG; Sandborn WJ
    Clin Pharmacol Ther; 1997 Mar; 61(3):340-8. PubMed ID: 9084459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis.
    Domènech E; Garcia-Planella E; Bernal I; Rosinach M; Cabré E; Fluvià L; Boix J; Gassull MA
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2061-5. PubMed ID: 12452938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.